Caribou Biosciences Shares Rise 4.1% as FDA Approves Lymphoma Trial
By Ben Glickman
Shares of Caribou Biosciences rose after the company's lymphoma trial design was approved by the Food and Drug Administration.
The stock was up 4.1% to $5.88 in after-hours trading following a 1.9% drop at Tuesday's close. Shares are down 10% this year.
The Berkeley, Calif.-based gene-editing pharmaceutical company said it had received feedback from the FDA on its Phase 3 trial for CB-010, a treatment for large B cell lymphoma.
The company plans to initiate its Phase 3 trial by the end of 2024.
The trial design includes platinum-based immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation.
Chief Executive Rachel Haurwitz said the FDA feedback was "an important step in advancing our lead therapy."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 12, 2023 18:11 ET (23:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States